131 related articles for article (PubMed ID: 9208981)
1. Comparison of an activated partial thromboplastin time with a Russell viper venom time test in screening for factor V(Leiden) (FVR506Q).
Sweeney JD; Blair AJ; King TC
Am J Clin Pathol; 1997 Jul; 108(1):74-7. PubMed ID: 9208981
[TBL] [Abstract][Full Text] [Related]
2. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Favaloro EJ; Mirochnik O; McDonald D
Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
[TBL] [Abstract][Full Text] [Related]
3. Whole blood screening test for factor V Leiden using a Russell viper venom time-based assay.
Akhtar MS; Blair AJ; King TC; Sweeney JD
Am J Clin Pathol; 1998 Apr; 109(4):387-91. PubMed ID: 9535390
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C.
Herskovits AZ; Lemire SJ; Longtine J; Dorfman DM
Am J Clin Pathol; 2008 Nov; 130(5):796-804. PubMed ID: 18854273
[TBL] [Abstract][Full Text] [Related]
5. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Baig MA
Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
[TBL] [Abstract][Full Text] [Related]
7. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation.
Aboud MR; Ma DD
Br J Haematol; 1997 Jun; 97(4):798-803. PubMed ID: 9217178
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
9. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
[TBL] [Abstract][Full Text] [Related]
10. Comparison between a one-point dilute phospholipid APTT and the dilute Russell viper venom time for verification of lupus anticoagulants.
Alving BM; Barr CF; Johansen LE; Tang DB
Thromb Haemost; 1992 Jun; 67(6):672-8. PubMed ID: 1509408
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous detection of FV Q506 and prothrombin 20210 A variation by allele-specific PCR.
Mitterer M; Lanthaler AJ; Mair W; Giacomuzzi K; Coser P
Haematologica; 1999 Mar; 84(3):204-7. PubMed ID: 10189382
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis of thrombophilia based on coagulation and genetic studies].
Bałszan-Kowalska I
Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477
[TBL] [Abstract][Full Text] [Related]
13. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
De Bel AV; Van der Cruyssen GA; Devreese KM
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
[TBL] [Abstract][Full Text] [Related]
14. Laboratory identification of lupus anticoagulants using the combination of activated partial thromboplastin time and Russell's viper venom at two phospholipid concentrations.
Akkawat B; Chantarangkul V; Rojnuckarin P; Juntiang J
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S451-8. PubMed ID: 12930024
[TBL] [Abstract][Full Text] [Related]
15. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
[TBL] [Abstract][Full Text] [Related]
16. Activated protein C resistance: the influence of ABO-blood group, gender and age.
Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L
Thromb Res; 2006; 117(6):665-70. PubMed ID: 16023702
[TBL] [Abstract][Full Text] [Related]
17. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
Viveros ME; Cabiedes J; Reyes E; Cabral AR
Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
[TBL] [Abstract][Full Text] [Related]
18. Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis.
Tripodi A; Negri B; Bertina RM; Mannucci PM
Thromb Haemost; 1997 Mar; 77(3):436-9. PubMed ID: 9065989
[TBL] [Abstract][Full Text] [Related]
19. Detection of factor V Leiden from a drop of blood by PCR-SSCP.
Corral J; Iniesta JA; González-Conejero R; Vicente V
Thromb Haemost; 1996 Nov; 76(5):735-7. PubMed ID: 8950782
[TBL] [Abstract][Full Text] [Related]
20. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
